NasdaqGS - Delayed Quote USD
Enliven Therapeutics, Inc. (ELVN)
18.42
-0.21
(-1.13%)
At close: May 9 at 4:00:02 PM EDT
18.42
0.00
(0.00%)
After hours: May 9 at 4:05:12 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Samuel S. Kintz M.B.A. | Co-Founder, CEO, Secretary & Director | 973.8k | -- | 1986 |
| Dr. Joseph P. Lyssikatos Ph.D. | Co-Founder & Chief Scientific Officer | 709.4k | -- | 1965 |
| Dr. Helen Louise Collins M.D. | Chief Medical Officer | 746.4k | -- | 1963 |
| Mr. Anish Patel Pharm.D. | Co-Founder & COO | -- | -- | 1980 |
| Mr. Benjamin Hohl | CFO & Head of Corporate Development | 488.5k | -- | 1989 |
| Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development | -- | -- | 1977 |
Enliven Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 62
Description
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Corporate Governance
Enliven Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 12, 2025 at 10:59 AM UTC - May 16, 2025 at 12:00 PM UTC
Enliven Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
CGEM Cullinan Therapeutics, Inc.
7.54
-2.96%
SYRE Spyre Therapeutics, Inc.
14.10
+9.64%
CNTA Centessa Pharmaceuticals plc
12.30
-0.73%
DNTH Dianthus Therapeutics, Inc.
19.59
-5.00%
ORKA Oruka Therapeutics, Inc.
9.54
-2.15%
BCAX Bicara Therapeutics Inc.
12.97
-1.22%
ANAB AnaptysBio, Inc.
19.59
+0.05%
IRON Disc Medicine, Inc.
44.24
-0.11%
NUVL Nuvalent, Inc.
69.85
-2.44%
MLTX MoonLake Immunotherapeutics
38.47
-3.20%